We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
- Authors
Oshita, Fumihiro; Sugiura, Makiko; Murakami, Shuji; Kondo, Tetsuro; Saito, Haruhiro; Yamada, Kouzo
- Abstract
Background: The standard chemotherapy for Japanese patients with extensive disease of small-cell lung cancer (ED-SCLC) is cisplatin and irinotecan. Methods: Patients with untreated ED-SCLC were treated with nedaplatin (NP) at 50 mg/m and irinotecan (CPT) at 50 mg/m on days 1 and 8 every 4 weeks for four cycles. Results: Twenty-five patients were registered. Nineteen patients were male and six female, with a median age of 64 years (50-79 years). Two patients had a performance status of 2. Nineteen of them were able to receive 4 courses of NP and CPT chemotherapy. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia occurred in 8.0, 68.0, and 36.0 % of patients, respectively. Other grade 3 toxicities were SGOT, hyponatremia, fatigue, vomiting, diarrhea, hypotension, febrile neutropenia, oral hemorrhage, and pneumonia. Grade 4 fatigue occurred in one patient. There was no treatment-related death. The overall response rate was 100 %. The median progression-free and overall survivals were 6.6 and 16.0 months, respectively, and the 2-year survival rate was 28 %. Conclusion: NP with CPT is effective and safe for patients with ED-SCLC.
- Subjects
IRINOTECAN; SMALL cell lung cancer; CANCER chemotherapy; JAPANESE people; HYPOTENSION; PERFORMANCE evaluation; PATIENTS; DISEASES
- Publication
Cancer Chemotherapy & Pharmacology, 2013, Vol 71, Issue 2, p345
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-012-2011-y